These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38992781)

  • 1. The relationship between Stroma AReactive Invasion Front Areas (SARIFA), Warburg-subtype and survival: results from a large prospective series of colorectal cancer patients.
    Offermans K; Reitsam NG; Simons CCJM; Grosser B; Zimmermann J; Grabsch HI; Märkl B; van den Brandt PA
    Cancer Metab; 2024 Jul; 12(1):21. PubMed ID: 38992781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroma AReactive Invasion Front Areas (SARIFA): a novel histopathologic biomarker in colorectal cancer patients and its association with the luminal tumour proportion.
    Reitsam NG; Grosser B; Enke JS; Mueller W; Westwood A; West NP; Quirke P; Märkl B; Grabsch HI
    Transl Oncol; 2024 Jun; 44():101913. PubMed ID: 38593584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Concept of Stroma AReactive Invasion Front Areas (SARIFA) as a new prognostic biomarker for lipid-driven cancers holds true in pancreatic ductal adenocarcinoma.
    Grochowski P; Grosser B; Sommer F; Probst A; Waidhauser J; Schenkirsch G; Reitsam NG; Märkl B
    BMC Cancer; 2024 Jun; 24(1):768. PubMed ID: 38926671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer.
    Enke JS; Groß M; Grosser B; Sipos E; Steinestel J; Löhr P; Waidhauser J; Lapa C; Märkl B; Reitsam NG
    BMC Cancer; 2024 Jan; 24(1):65. PubMed ID: 38216952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations in Natural Killer Cells in Colorectal Cancer Patients with Stroma AReactive Invasion Front Areas (SARIFA).
    Reitsam NG; Märkl B; Dintner S; Sipos E; Grochowski P; Grosser B; Sommer F; Eser S; Nerlinger P; Jordan F; Rank A; Löhr P; Waidhauser J
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biomarker SARIFA in colorectal cancer: highly prognostic, not genetically driven and histologic indicator of a distinct tumor biology.
    Reitsam NG; Grozdanov V; Löffler CML; Muti HS; Grosser B; Kather JN; Märkl B
    Cancer Gene Ther; 2024 Feb; 31(2):207-216. PubMed ID: 37990064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroma AReactive Invasion Front Areas (SARIFA) - a new prognostic biomarker in gastric cancer related to tumor-promoting adipocytes.
    Grosser B; Glückstein MI; Dhillon C; Schiele S; Dintner S; VanSchoiack A; Kroeppler D; Martin B; Probst A; Vlasenko D; Schenkirsch G; Märkl B
    J Pathol; 2022 Jan; 256(1):71-82. PubMed ID: 34580877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converging deep learning and human-observed tumor-adipocyte interaction as a biomarker in colorectal cancer.
    Reitsam NG; Grosser B; Steiner DF; Grozdanov V; Wulczyn E; L'Imperio V; Plass M; Müller H; Zatloukal K; Muti HS; Kather JN; Märkl B
    Commun Med (Lond); 2024 Aug; 4(1):163. PubMed ID: 39147895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroma AReactive Invasion Front Areas (SARIFA) proves prognostic relevance in gastric carcinoma and is based on a tumor-adipocyte interaction indicating an altered immune response.
    Grosser B; Heyer CM; Austgen J; Sipos E; Reitsam NG; Hauser A; VanSchoiack A; Kroeppler D; Vlasenko D; Probst A; Novotny A; Weichert W; Keller G; Schlesner M; Märkl B
    Gastric Cancer; 2024 Jan; 27(1):72-85. PubMed ID: 37874427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trial.
    Grosser B; Emmerson J; Reitsam NG; Cunningham D; Nankivell M; Langley RE; Allum WH; Trepel M; Märkl B; Grabsch HI
    Br J Cancer; 2024 Feb; 130(3):457-466. PubMed ID: 38123705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroma AReactive Invasion Front Areas (SARIFA) predict poor survival in adenocarcinomas of the stomach and gastrooesophageal junction: a validation study.
    Ulase D; Behrens HM; Röcken C
    Virchows Arch; 2024 Sep; 485(3):527-534. PubMed ID: 38748262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroma AReactive Invasion Front Areas (SARIFA)-A New Easily to Determine Biomarker in Colon Cancer-Results of a Retrospective Study.
    Martin B; Grosser B; Kempkens L; Miller S; Bauer S; Dhillon C; Banner BM; Brendel EM; Sipos É; Vlasenko D; Schenkirsch G; Schiele S; Müller G; Märkl B
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between adjuvant therapy and survival in colorectal cancer patients according to metabolic Warburg-subtypes.
    Offermans K; Jenniskens JCA; Simons CCJM; Samarska I; Fazzi GE; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6271-6282. PubMed ID: 36723668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the Warburg effect in tumour cells and the tumour microenvironment in colorectal cancer patients: Results from a large multicentre study.
    Steeghs JPJM; Offermans K; Jenniskens JCA; Samarska I; Fazzi GE; van den Brandt PA; Grabsch HI
    Pathol Res Pract; 2023 Jul; 247():154518. PubMed ID: 37209573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of proteins associated with the Warburg-effect and survival in colorectal cancer.
    Offermans K; Jenniskens JC; Simons CC; Samarska I; Fazzi GE; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    J Pathol Clin Res; 2022 Mar; 8(2):169-180. PubMed ID: 34791830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local Invasion Patterns Characterized by SARIFA and Tumor Budding Differ and Have Distinct Prognostic Significance in Esophageal Adenocarcinoma and Squamous Cell Carcinoma.
    Jakab Á; Zarándy L; Kocsmár I; Várkonyi T; Kenessey I; Szijártó A; Kiss A; Vass T; Lotz G; Kocsmár É
    Cancers (Basel); 2024 Sep; 16(18):. PubMed ID: 39335115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between mutational subgroups, Warburg-subtypes, and survival in patients with colorectal cancer.
    Offermans K; Jenniskens JCA; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    Cancer Med; 2023 Jan; 12(2):1137-1156. PubMed ID: 35785488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [SARIFA-a new multi-entity biomarker].
    Grosser B; Reitsam NG; Grochowski P; Rentschler L; Enke J; Märkl B
    Pathologie (Heidelb); 2024 Nov; 45(6):397-403. PubMed ID: 39365350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SARIFA biomarker in the context of basic research of lipid-driven cancers.
    Märkl B; Reitsam NG; Grochowski P; Waidhauser J; Grosser B
    NPJ Precis Oncol; 2024 Jul; 8(1):165. PubMed ID: 39085485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.
    Hatthakarnkul P; Pennel K; Alexander P; van Wyk H; Roseweir A; Inthagard J; Hay J; Andersen D; Maka N; Park J; Roxburgh C; Thuwajit C; McMillan D; Edwards J
    J Pathol Clin Res; 2024 May; 10(3):e12374. PubMed ID: 38650367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.